You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Koch Disruptive Technologies, Longliv Ventures, and OurCrowd participated in the round, bringing the firm's total funding to date to more than $124 million.
Pathnova, will further develop and commercialize Todos' tests in Singapore, while Todos will assist Pathnova to commercialize its nasopharyngeal cancer tests.
The agreement is Oncocyte's second distribution deal this year following an agreement with Core Diagnostics to sell the test in Africa and the Middle East.
Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.
Todos said that it aims to develop an at-home 3C protease-based kit that uses a cell-phone camera and software for data analysis to test for the coronavirus.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
Todos said it believes that gaining access to a medical grade ventilator will bring further attention to its coronavirus tests.
The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
The point-of-care system is designed to measure glycated hemoglobin levels in whole blood for use in the monitoring and management of diabetes.
The company is completing a study of its digital microscopy system which uses a computational approach that it said enables high-speed, high-resolution scanning.